No Data
No Data
Express News | Eyenovia Inc - Requested Meeting With FDA to Discuss Validation of the Gen-2 Dispenser, Which We Anticipate Will Occur This Summer
Express News | Eyenovia, Inc. Q1 Operating Expenses USD 10.3 Million
Express News | Eyenovia, Inc. Q1 Net Income USD -10.9 Million
Express News | Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on Its Myopia Phase III Program and Its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
Express News | Eyenovia, Inc. Q1 Basic EPS USD -0.23
Eyenovia 1Q Loss/Shr 23c >EYEN
Eyenovia 1Q Loss/Shr 23c >EYEN
No Data